Despite recent advances in cancer research and treatment, CRC remains among the deadliest malignancies worldwide.1,2 Notably, more than 80% of CRC cases harbor loss-of-function mutations in the Apc gene,14–16 emphasizing the critical need to understand the function of APC in CRC pathogenesis in order to develop more effective therapies for this patient population. This evidence concerns the gene APC and cancer.